Treatment of diffuse in-stent restenosis with rotational atherectomy followed by radiation therapy with a rhenium-188–mercaptoacetyltriglycine-filled balloon  by Park, Seong-Wook et al.
Treatment of Diffuse In-Stent Restenosis
With Rotational Atherectomy Followed
by Radiation Therapy With a
Rhenium-188–Mercaptoacetyltriglycine-Filled Balloon
Seong-Wook Park, MD, PHD, FACC,* Myeong-Ki Hong MD, PHD,* Dae Hyuk Moon, MD, PHD,†
Seung Jun Oh, PHD,† Cheol Whan Lee, MD,* Jae-Joong Kim, MD, PHD*
Seung-Jung Park, MD, PHD, FACC*
Seoul, Korea
OBJECTIVES This study was done to evaluate the feasibility and efficacy of beta-radiation therapy with a
rhenium-188 –mercaptoacetyltriglycine (188Re-MAG3)-filled balloon after rotational
atherectomy for diffuse in-stent restenosis (ISR).
BACKGROUND Rotational atherectomy has been shown to be safe and efficient for the treatment of ISR, but
the recurrence rate is still high. Intracoronary beta-irradiation after rotational atherectomy
may be a reasonable approach to prevent recurrent ISR.
METHODS Fifty consecutive patients with diffuse ISR (length .10 mm) in native coronary arteries
underwent rotational atherectomy and adjunctive balloon angioplasty, followed by beta-
irradiation using a 188Re-MAG3–filled balloon catheter. The radiation dose was 15 Gy at a
depth of 1.0 mm into the vessel wall.
RESULTS The mean lengths of the lesion and irradiated segment were 25.6 6 12.7 mm and 37.6 6
11.2 mm, respectively. Radiation was delivered successfully to all patients, with a mean
irradiation time of 201.8 6 61.7 s. No adverse event, including myocardial infarction, death
or stent thrombosis, occurred during the follow-up period (mean 10.3 6 3.7 months), and
nontarget vessel revascularization was needed in one patient. The six-month binary
angiographic restenosis rate was 10.4%, and the loss index was 0.17 6 0.31.
CONCLUSIONS Beta-irradiation using a 188Re-MAG3–filled balloon after rotational atherectomy is safe and
feasible in patients with diffuse ISR, and it may improve their clinical and angiographic
outcomes. Further prospective, randomized trials are warranted to evaluate the synergistic
effect of debulking and irradiation in patients with diffuse ISR. (J Am Coll Cardiol 2001;38:
631–7) © 2001 by the American College of Cardiology
Intracoronary stenting reduces restenosis, as compared with
balloon angioplasty (percutaneous transluminal coronary
angioplasty [PTCA]). However, in-stent restenosis (ISR)
develops in a significant proportion of patients, particularly
in those with multiple or long stents. In-stent restenosis
remains an important clinical problem, because the recur-
rence rate is high with repeat PTCA, especially in diffuse
ISR (1,2). Previous studies have shown that rotational
atherectomy may improve the long-term clinical outcome in
patients with diffuse ISR, but the incidence of major adverse
cardiac events (MACE) is still high (3–5). Recently, several
studies have demonstrated the efficacy of local gamma- or
beta-irradiation in patients with ISR (6–8). The major
advantage of beta-irradiation is its low penetration depth,
thus minimizing the radiation exposure to the patient and
the operator and decreasing the potential damage to the
adjacent normal tissue. However, the rapid fall-off of
radiation dose within 2 mm may be associated with an
inhomogeneous dose delivery to the target tissue, especially
in the vessel with very eccentric atheromatous plaque.
Intracoronary irradiation using a radioactive solution-filled
balloon is a simple and inexpensive method to deliver
radiation to the vessel wall. With only a few modifications,
it can be applied to coronary arteries, even those with a large
diameter or angulated arterial segments. In addition, the
dose distribution is uniform, without the aid of centering
devices (9). Rhenium-188 (188Re) is a beta-emitting radio-
nuclide with a short half-life of 17 h and other suitable
physicochemical properties, and it acts as a therapeutic
radioisotope (9). The purchase of a tungsten-188 (188W)/
188Re generator enables daily milking of high activity of
188Re solutions for several months.
We presumed that beta-irradiation with 188Re after
effective rotational atherectomy may improve the delivery of
an optimal radiation dose to the target tissue, which could
translate into improvement in the patient’s long-term clin-
ical outcome. The purpose of this study was to evaluate the
feasibility and efficacy of intracoronary beta-radiation ther-
apy with a 188Re-mercaptoacetyltriglycine (MAG3)–filled
balloon after rotational atherectomy in patients with diffuse
ISR (R4 registry).
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METHODS
Study group. Fifty consecutive patients with diffuse ISR
were prospectively evaluated at the at Asan Medical Center
between March 1999 and February 2000. Inclusion criteria
were diffuse ISR (lesion length .10 mm, diameter stenosis
.50%) in a native coronary artery with angina, demonstra-
ble myocardial ischemia and written, informed consent.
Exclusion criteria were acute myocardial infarction (MI)
within 72 h, poor renal function (serum creatinine .3.0
mg/dl), pregnancy, contraindication to antiplatelet therapy
and concomitant serious disease with expected survival of
,2 years. In patients with multiple ISR, only one lesion was
treated with radiation therapy. Additional new stent im-
plantation was strongly discouraged, although not contra-
indicated. During the study period, rotational atherectomy
and adjunct balloon angioplasty without radiation therapy
were successfully performed in nine patients with diffuse
ISR who refused to join this study. Our Institutional
Review Board approved this study.
Radiation delivery system, dosimetry and procedure.
The radiation system was a 188Re-MAG3–filled angioplasty
balloon. Rhenium-188 is a high-energy beta-emitter with a
maximal energy of 2.12 MeV that is available daily as
188Re-perrhenate solution from the 188W/188Re generator
(Oak Ridge National Laboratory, Oak Ridge, Tennessee)
and has a half-life of 17 h. Highly concentrated (3.7 to
11.1 GBq/ml) 188Re-MAG3 solution was prepared from
188Re-perrhenate and MAG3 (Technescan, Mallinckrodt
Medical, St. Louis, Missouri), using the synthesizer devel-
oped at our institution (10), which is a compressed air–
driven, semi-automated, shielded system. Rhenium-188–
MAG3 was purified and concentrated by C18 Sep-Pak
cartridges to the desired radioactivity and volume, and then
it was mixed with ionic contrast agent (Hexabrix, Guerbet,
France) to make a final iodine concentration to 20%
(vol/vol). To minimize the operator’s exposure to radiation,
a syringe with 1.5 ml of 188Re-MAG3 was shielded with a
beta-and gamma-shielding syringe holder (10-mm acryl and
20-mm lead). The isotope-containing syringe with the
shielding syringe holder was put inside a plastic box to avoid
possible radioisotope contamination of the operating table
(Fig. 1). Before this clinical trial, we performed a detailed
dosimetric study using the Monte Carlo simulation method.
Attenuation due to iodine contrast media, the balloon and
the guide wire was considered in this simulation model. The
overall dose reductions caused by the presence of the central
lumen of the balloon, balloon wall and contrast medium
were 5.6%, 7.7% and 9.1% at the 3.0-mm diameter balloon
surface for 10%, 20% and 30% of contrast media in the
188Re solution, respectively. Dose rates at 1.0 mm from the
surface of a balloon filled with 3.7 GBq/ml of 188Re and
20% Hexabrix were 1.65, 1.98, 2.26 and 2.51 Gy/min for a
2.5-, 3.0-, 3.5- and 4.0-mm diameter balloon, respectively.
We also performed experimental dosimetric studies using
the GafChromic (Agfa Co.) film and tissue equivalent
phantoms for balloons of 2.5, 3.0, 3.5 and 4.0 mm in
diameter. The average difference between measured and
calculated radial doses around the balloon was 6.6% for
distances at 0.5 to 1 mm from the balloon surface. From the
dosimetric data, the irradiation time was calculated to
deliver 15 Gy at a depth of 1.0 mm into the vessel wall from
the balloon–artery interface, depending on the size of the
balloon and the actual radioactivity of 188Re-MAG3 solu-
tion. Radiation exposure to the operator was ,5 mSv per
treatment.
All patients were pretreated with aspirin (200 mg/day),
ticlopidine (500 mg/day) and cilostazol (200 mg/day) for
two days. Ticlopidine was given for one month, but aspirin
and cilostazol were administered for more than six months
after irradiation. Rotational atherectomy and adjunctive
PTCA were performed to obtain an optimal angiographic
result (diameter stenosis ,20%). Coronary angiograms were
obtained at each step to determine the actual segment
treated with atherectomy and PTCA. The long conven-
tional balloon (30 and 40 mm in length; Boston Scientific
Corporation, San Jose, California), which was the same
kind of balloon used for the dosimetric study, was selected
for irradiation to cover the proximal and distal uninjured
margin of at least 5 mm. For long ISR (.30 mm) that could
not be covered by a single long balloon, manual stepping
was permitted, with minimal overlapping. The 188Re-
Abbreviations and Acronyms
CSA 5 cross-sectional area
EEM 5 external elastic membrane
IH 5 intimal hyperplasia
ISR 5 in-stent restenosis
IVUS 5 intravascular ultrasound
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PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary angiography
188Re 5 rhenium-188
Figure 1. Safety box containing a radioisotope-filled syringe shielded with
polyethylene and lead.
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MAG3–filled syringe and conventional in-deflator device
were connected to the balloon by three-way valves (Fig. 1).
After complete removal of air from the balloon, 188Re-
MAG3 solution was introduced into the balloon manually.
Inflation of the balloon was maintained with the nominal
inflation pressure of 6 atm. Fractionation was allowed in
case of severe angina or significant hemodynamic changes.
After irradiation, the whole system was removed and
brought to the Department of Nuclear Medicine for decay.
Quantitative coronary angiography (QCA). Coronary
angiograms were analyzed by two experienced angiogra-
phers using an on-line QCA system (ANCOR version 2.0,
Siemens, Germany). Angiographic measurements were
made during diastole after intracoronary nitroglycerin ad-
ministration, using the guiding catheter for magnification
calibration. Single matched views with the worst diameter
stenosis were compared.
Intravascular ultrasound (IVUS) imaging. Preradiation,
postradiation and follow-up IVUS studies were performed
in identical fashion in 44 of 50 patients, using a commer-
cially available system (Boston Scientific Corporation/ Car-
diovascular Imaging System, Inc., San Jose, California).
With this system, the transducer was withdrawn automat-
ically at 0.5 mm/s to perform the imaging sequence. The
cross-sectional area (CSA) measurements of the external
elastic membrane (EEM), lumen, plaque plus media by
IVUS have been reported previously (11,12). The EEM
CSA (representing total arterial CSA) was measured by
tracing the leading edge of the adventitia. The plaque plus
media CSA (representing atherosclerotic plaque) was cal-
culated as the EEM CSA minus the lumen CSA. Plaque
burden was measured as the plaque plus media CSA divided
by the EEM CSA. The intimal hyperplasia (IH) CSA was
measured as the stent CSA minus the lumen CSA, and
percent IH CSA as 100 3 (IH CSA/stent CSA). The
proximal and distal reference segments and irradiated seg-
ments were assessed quantitatively.
Primary and secondary end points. All patients were
evaluated clinically during an office visit at one, three and six
months, and then every four months after radiation therapy.
Repeat coronary angiography and IVUS were performed at
six months after irradiation, or earlier if clinically indicated.
Major adverse cardiac events, including death, nonfatal MI
and repeat revascularization, were evaluated. The primary
end point was the occurrence of any MACE during the
follow-up period. Myocardial infarction was diagnosed
when cardiac enzymes were elevated threefold or greater,
with chest pain lasting .30 min or with the appearance of
new electrocardiographic changes. The secondary end point
was the angiographic incidence of restenosis (diameter
stenosis .50%) and a loss index by QCA. Intravascular
ultrasound variables were also analyzed.
Statistical analysis. The results are presented as the mean
value 6 SD or number (%) of patients. Serial changes of
continuous variables were compared by repeated measures
analysis of variance and a multiple comparisons procedure
with the Bonferroni correction. A p value ,0.05 was
considered statistically significant.
RESULTS
In-hospital outcomes and procedural results. Fifty con-
secutive patients (42 men, 55.7 6 9.0 years old) underwent
successful radiation therapy after rotational atherectomy and
adjunctive balloon angioplasty. Their clinical characteristics
were unstable angina in 66% and stable angina in 34%.
Their risk factors included hypertension in 38%, diabetes
mellitus in 26%, hypercholesterolemia in 24% and current
smoking status in 62%. Eight patients (16%) had an old MI,
and seven patients (14%) had experienced at least one
intervention for recurrent ISR. The mean left ventricular
ejection fraction was 60.2 6 6.8%. The mean burr size of
rotational atherectomy was 2.06 6 0.21 mm, and the
burr/artery ratio was 0.72 6 0.09. Adjunctive balloon
angioplasty was performed in all patients to obtain optimal
angiographic results, with a mean balloon/artery ratio of
1.23 6 0.20. No patient received additional new stent
implantation. The maximal inflation pressure was 9.1 6
3.8 atm. The mean lengths of the lesion and irradiated
segment were 25.6 6 12.7 mm and 37.6 6 11.2 mm,
respectively. The mean irradiation time was 201.8 6 61.7 s.
Fractionation was needed in six patients, and stepping of a
30-mm balloon was done in seven patients. No procedure-
related complications or in-hospital MACE occurred.
Primary and secondary end points. At a mean of 10.3 6
3.7 months of clinical follow-up, MACE had occurred in
one patient (2%); repeat revascularization was needed be-
cause of aggravation of stenosis at the ostium of the left
main coronary artery, which was not related to the previous
irradiation. Death, MI or stent thrombosis did not occur in
any patients during the follow-up period. Angiographic
follow-up was done in 48 patients (follow-up up rate of
96%) at 5.8 6 1.7 months after irradiation. The quantitative
angiographic results are shown in Table 1. An example of a
6-month follow-up angiogram after radiation therapy is
shown in Figure 2. Binary angiographic restenosis occurred
in five patients; thus, the overall angiographic restenosis rate
was 10.4%. The remaining two patients who refused angio-
graphic follow-up were free of angina. The late loss index
was 0.17 6 0.31. The pattern of restenosis included two
focal ISRs and three edge restenoses (one in the proximal
and two in the distal edge), with a mean of 57.2 6 5.2%
lumen diameter stenosis. These patients with recurrent
restenosis, however, did not undergo a further coronary
intervention because they had either mild angina (n 5 3) or
absence of a perfusion abnormality on the thallium perfu-
sion single-photon emission computed tomographic image
(n 5 2). Fractionation or stepping of the radiation balloon
was not associated with any clinical events or late angio-
graphic aneurysm formation.
The IVUS findings are shown in Table 2. There was no
significant difference in stent CSA, lumen CSA, IH CSA or
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percent IH CSA between the post-radiation and follow-up
studies. In 19 (43%) of 44 lesions, the minimal in-stent
lumen CSA at six-month follow-up was larger than that
immediatly after irradiation.
DISCUSSION
This study is the first to indicate the feasibility and safety of
intracoronary beta-irradiation combined with rotational
atherectomy to prevent recurrent ISR in patients with
diffuse ISR.
Comparison with previous studies. Because this study
was based on a registry, the effectiveness of beta-irradiation
with 188Re-MAG3 after atherectomy may not be conclusive.
The incidences of MACE and angiographic restenosis at six
months, however, were at least similar to or lower than
those of other trials of irradiation or rotational atherectomy
alone. Considering the long lesion length (25.5 6 12.7 mm)
in this study, the angiographic restenosis of 10.4% and the
loss index of 0.17 are very encouraging. In the previous
rotational atherectomy trial of ISR, the rates of repeat ISR
and target vessel revascularization were 28% and 26%,
respectively, at a mean follow-up of 13 6 5 months (3). In
another study, the incidences of one-year MACE after
rotational atherectomy for diffuse ISR were 5% for death,
2% for Q-wave MI and 28% for overall target lesion
revascularization (4). Previous clinical trials with radiation
therapy for ISR showed six-month MACE and angio-
graphic restenosis rates as follows: Scripps Coronary Radi-
ation to Inhibit Proliferation Post-Stenting (SCRIPPS):
MACE in 19% and restenosis in 17% (6); gamma-
Washington Radiation for In-Stent Restenosis Trial
(WRIST): target vessel revascularization in 26.2% and
restenosis in 19% (7); and beta-WRIST: target vessel
revascularization in 34% and restenosis in 22% (8).
The clinical results of radiation therapy with liquid 188Re
for human coronary stenosis were first reported by Ho¨her et
al. (13). They demonstrated the technical feasibility and
safety of the liquid isotope-filled balloon system in 100% of
patients treated, but the restenosis rate (46%) and the late
loss index (0.57 6 0.57) at six months were relatively high.
There are many differences between this study and ours in
terms of the methodologic aspects. First, the study popula-
tion is different. Ho¨her et al. (13) included de novo lesions,
whereas our study included solely ISR. Second, the use of
rotational atherectomy and optimal balloon angioplasty
before irradiation in the current study may have favorably
influenced the late angiographic and clinical outcomes.
Rather, aggressive balloon dilation strategy (mean balloon/
artery ratio of 1.23 6 0.20) was applied according to the
IVUS findings, which was not associated with significant
complications. The radiation dose was also different be-
tween the two studies: 15 Gy at 0.5 mm (Ho¨her et al.)
versus 15 Gy at a depth of 1 mm into the tissue. However,
it is not clear whether the difference in the radiation dose
made a significant difference in the outcomes, considering
the different target lesions (i.e., de novo vs. ISR) The
presence of a stainless-steel stent is known to reduce the
radiation dose by 4% to 14%, depending on the design and
structure of the stent (14). In addition to the differences
described earlier, the use of a contrast agent to fill the
radiation balloon needs to be considered. Insertion of a
radiopaque contrast medium allows fluoroscopic verification
of complete inflation of the balloon at the exact segment
that is being treated. The radiation dose immediately
adjacent to an air bubble was shown to be 30% lower than
that for a filled balloon (15). Ho¨her et al. (13) did not assess
the complete filling of the radioisotope without air bubbles
at the time of irradiation, although it was demonstrated in
their in vitro studies. Furthermore, 16 of 28 patients
required radiation dose fractionation, which might have
increased the chance of air inclusion in the balloon. In this
regard, we believe that the addition of a contrast medium to
the liquid isotope is essential for intracoronary radiation
therapy using a 188Re-filled balloon. Recently, Fox and
Henson (16) reported the fractional dose correction values
for 33% of the contrast medium in saline, using the point
kernel method. A dose reduction of 7.4% at 0.02 mm from
the 3.2-mm diameter balloon surface was comparable to our
previous result of 6.5% dose reduction at the surface of a
3.0-mm diameter balloon filled with 30% contrast medium.
Clinical applications and safety issue. There are many
advantages to using a liquid 188Re-filled angioplasty balloon
for radiation therapy. This method can be applied to vessels
of various sizes and at the angulated segment, without
significant technical difficulty. Technical failure was absent
in the present study. Besides versatile application and technical
feasibility, there is a theoretical advantage of uniform dose
distribution of radiation, because centering is not an impor-
tant issue with this method. The potential disadvantages
of this method would be radiation exposure to the patient
in case of balloon leakage and contamination of the
operating table during the procedure. The risk of contam-







.10, #20 21 (42%)
.20, #30 13 (26%)
.30 16 (32%)
Reference vessel diameter (mm) 2.89 6 0.40
Minimal lumen diameter (mm)
Before intervention 0.60 6 0.44
After intervention 2.68 6 0.39
Follow-up 2.30 6 0.61
Early gain (mm) 2.08 6 0.46
Late loss (mm) 0.37 6 0.65
Loss index 0.17 6 0.31
Binary restenosis rate (%) 10.4
Data are presented as the number (%) of patients or mean value 6 SD.
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; LMCA 5 left main stem coronary artery; RCA 5 right coronary artery.
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ination with an isotope in the catheterization laboratory,
however, can virtually be eliminated with the use of a safety
box and careful handling of the radiation source. Highly
concentrated liquid 188Re-MAG3 (3.7 to 11.1 GBq/ml) was
used in this study to shorten the balloon inflation time and
to obviate the need for dose fractionation, which may
increase the chance of air inclusion in the balloon. Only six
patients (12%) needed fractionation of the radiation dose.
For the safety of the patients, in case of balloon rupture, an
in vivo experiment with a whole-body scan was performed
in pigs before the human trial. After intracoronary injection
of 370 MBq of 188Re-MAG3 solution, rapid urinary excre-
tion of 188Re-MAG3 was confirmed, with no significant
isotope activity in other organs in 60 min. The absorbed
dose in the whole body was 0.01 mGy/MBq. Rhenium-
188–MAG3 was first introduced in intracoronary radiation
therapy because of its rapid renal excretion, which facilitates
its removal from the body in case of balloon rupture (9).
Previous studies have demonstrated that 188Re-labeled
MAG3 has the lowest internal radiation dose among three
188Re radiopharmaceutical agents, in case of balloon rup-
ture, because of its rapid renal excretion (17). If radiation
therapy is performed using liquid 188Re-MAG3 of 11.1
GBq/ml and a balloon catheter of 3.0 mm in diameter and
30 mm in length, 2.35 GBq 188Re-MAG3 would be
released from the balloon in the event of balloon rupture.
This radioactivity would result in a whole-body absorbed
dose of 25.6 mGy, which is equivalent to only 1/100 of the
minimal tolerance dose of bone marrow (2,500 mGy) (17).
In this study, we synthesized highly concentrated 188Re-
MAG3 by using an automated synthesis system to minimize
radiation exposure to personnel who are involved in the
routine preparation (10). The preparation of 188Re-MAG3
by using the automated system was simple, as well as
reproducible in obtaining high radiolabeling yields .95%.
The total preparation time was ,30 min.
Figure 2. An example of radiation therapy with a 188Re-MAG3–filled
balloon catheter. (A) Diffuse in-stent restenosis (arrow) at the proximal left
anterior descending coronary artery. (B) Final angiogram after radiation
therapy. (C) Six-month follow-up angiogram.








EEM CSA (mm2) 9.7 6 3.0 11.6 6 3.2 12.0 6 3.4
Lumen CSA (mm2) 5.2 6 1.7 6.4 6 1.7 6.2 6 1.9
P 1 M CSA (mm2) 4.5 6 1.7 5.2 6 1.8 5.8 6 2.3
Plaque burden (%) 46 6 9 45 6 7 47 6 10
In-stent restenotic lesion
Stent CSA (mm2) 7.4 6 2.1 8.6 6 2.4 8.7 6 2.4
Lumen CSA (mm2) 1.6 6 0.4 5.5 6 1.5 5.1 6 2.0
IH CSA (mm2) 5.7 6 1.9 3.0 6 1.3 3.5 6 1.8
Percent IH CSA (%) 77 6 6 35 6 8 40 6 17
Proximal reference segment
EEM CSA (mm2) 15.2 6 3.5 15.7 6 3.5 16.1 6 3.5
Lumen CSA (mm2) 7.3 6 2.5 8.0 6 2.5 7.6 6 2.4
P 1 M CSA (mm2) 7.9 6 1.9 7.7 6 2.0 8.4 6 2.1
Plaque burden (%) 53 6 9 50 6 9 53 6 9
Data are presented as the mean value 6 SD.
CSA 5 cross-sectional area; EEM 5 external elastic membrane; IH 5 intimal
hyperplasia; P 1 M 5 plaque and media.
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Edge restenosis. Edge restenosis has been an important
issue associated with radiation therapy, especially with
radioactive stents (18). The pathophysiology of the edge
effect may be the result of vessel wall injury concomitant
with low-dose radiation at the edges of the irradiated area
(“geographic miss”) (19). In the current study, the incidence
of edge restenosis was 6%, which was much lower than that
in previously reported studies. Ho¨her et al. (13) reported a
high incidence (35%) of edge restenosis, in which the length
of the radiation balloon was the same as that of the dilation
balloon. The use of a long balloon or stepping of the balloon
for irradiation in the current study may have reduced the
incidence of edge restenosis. Although every effort was
made to irradiate the proximal and distal uninjured margin
at least 5 mm, post hoc detailed angiographic analysis
revealed that geographic miss was present in 55.6% of
treated margins. The three patients with edge restenosis also
had geographic miss. The results of this and previous studies
indicate that the radiation balloon should be sufficiently
longer than the injured segment to avoid geographic miss
(“the longer, the better”).
Intravascular ultrasound findings. The effect of irradia-
tion on the intimal hyperplasia was evaluated with serial
IVUS studies. The small, nonsignificant changes of percent
IH CSA within the stent (35% after radiation to 40% at
follow-up) during the follow-up period are believed to be
the result of excellent inhibition of neointimal hyperplasia
formation by irradiation, which could result in the mainte-
nance of a widely patent lumen at follow-up. The findings
of the current study were similar to the results of IVUS
analysis in the beta-WRIST trial involving ISR (20).
Furthermore, in 19 (43%) of 44 lesions with IVUS follow-
up, the minimal in-stent lumen CSA at follow-up was
larger than that after irradiation. This finding suggests that
the regression of neointimal tissue within the stent occurred
by means of irradiation during the follow-up period. A
similar finding was also noticed in 53.2% of the lesions with
radiation in WRIST trial (7).
Late thrombosis. Late thrombosis is a valid concern after
radiation therapy. The rate of late total occlusion has been
reported to be up to 10% (21). In this study, there has been
no late occlusion until now. Plausible explanations may be
avoidance of new stent implantation and continued admin-
istration of aspirin and cilostazol for more than six months.
Cilostazol has been demonstrated to have an antithrombotic
efficacy similar to that of ticlopidine and to reduce restenosis
rate after PTCA (22,23). The antiproliferative effect of
cilostazol might have possibly contributed, in part, to the
low incidence of restenosis in the current trial. The benefi-
cial effect of long-term use of cilostazol after radiation
therapy needs to be determined.
Study limitations. The results are based on a registry data.
Because of the lack of a control group, we could not prove
the efficacy of beta-irradiation after rotational atherectomy
in patients with diffuse ISR. The number of study patients
is relatively small. The real beneficial effect of atherectomy
before beta-irradiation should be evaluated in prospective,
randomized clinical trials including a large number of
patients. Regarding the safety of beta-irradiation combined
with rotational atherectomy, our study is limited to the
procedural results and six-month follow-up. However, there
was no increased incidence of MACE in patients who
passed six months of follow-up. Longer term clinical
follow-up results will be reported in the future. Finally, in
many cases, IVUS evaluation was done before the interven-
tion to select the appropriate size of the atherectomy burr
and dilation balloon, which could have influenced the
selection of devices. It remains to be determined whether an
angiography-guided approach would result in similar angio-
graphic and clinical outcomes.
Conclusions. Radiation therapy with beta-emitting 188Re-
MAG3 after rotational atherectomy is technically feasible
and safe for diffuse ISR. The six-month clinical event rates
and angiographic restenosis rates were low. The results of
this study suggest that beta-irradiation using 188Re-MAG3
combined with rotational atherectomy may be a viable
therapeutic modality for patients with diffuse ISR. Further
prospective, randomized studies comparing beta-irradiation
plus atherectomy with beta-irradiation alone need to be
done to elucidate the role of debulking for radiation therapy
in diffuse ISR.
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